ELDN — Eledon Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $186.90m
- $137.16m
Brief: Eledon Pharmaceuticals Appoints Eliezer Katz as Chief Medical Officer
Brief: Eledon Pharmaceuticals Announces First Participant Dosed In Phase 2 BESTOW Trial
Brief: Eledon Pharmaceuticals Announces Dosing Of 10Th Patient In Ongoing Phase 1B Trial Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation
Eledon Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Eledon Pharmaceuticals Inc expected to post a loss of 46 cents a share - Earnings Preview
Brief: Eledon Pharmaceuticals Inc Files For Offering Of 75.8 Million Shares Of Common Stock Offered By Selling Stockholders - SEC Filing
Eledon Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Eledon Pharmaceuticals Reports First Quarter 2023 Operating And Financial Results
Eledon Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Eledon Pharmaceuticals Announces Up To $185 Million Financing To Advance Tegoprubart Kidney Transplantation Clinical Trials
Brief: Eledon Reports Data From Ongoing Phase 1b Trial Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At World Congress Of Nephrology
Eledon Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Eledon Pharmaceuticals Inc Reports Net Loss Of $58.4 Million, Or $4.09 Per Share, For Three Months Ended December 31, 2022
Eledon Pharmaceuticals Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Eledon To Present Data From Ongoing Phase 1B Trial Evaluating Tegoprubart In Kidney Transplantation At The World Congress Of Nephrology 2023
Eledon Pharmaceuticals Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Egenesis And Eledon Pharmaceuticals Announce Collaboration For Use Of Tegoprubart In Preclinical Xenotransplantation Studies
Brief: Eledon Pharmaceuticals Provides Business And Pipeline Updates
Brief: C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion For Ibox Scoring System